Prashant Gajwani, MD
Psychiatry · Houston, TXNPI 1770509283
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $250,595 of the $355,028 with a category attached, or 70.6%. 32 manufacturers reported payments, led by Johnson & Johnson at 54.8% of the total. 2025 is the largest year on record at $113,825, 3.2 times the $35,737 reported in 2019. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 971 payments — averaging $365.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$195K
- Axsome Therapeutics, Inc.$124K
- Sunovion Pharmaceuticals Inc.$19K
- Neurocrine Biosciences, Inc.$5K
- Merck$3K
- AbbVie$2K
- plus $7K from 26 others
Across 37 payments — averaging $2605.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Hoffmann-la Roche Limited$30K
- Genentech, Inc.$20K
- AbbVie$15K
- Boehringer Ingelheim$11K
- Biohaven Pharmaceuticals, Inc.$11K
- Livanova USA, Inc.$9K
What the payments were for
- Consulting fees$51,44514%
- Speaking & faculty fees$250,59571%
- Travel & lodging$34,85010%
- Food & beverage$17,8755%
- Education$2630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 328 | $194,702 |
| Axsome Therapeutics, Inc. | 149 | $124,111 |
| Sunovion Pharmaceuticals Inc. | 59 | $19,355 |
| Neurocrine Biosciences, Inc. | 34 | $5,129 |
| Merck | 8 | $2,980 |
| AbbVie(2 entities) | 106 | $1,773 |
| Livanova USA, Inc. | 6 | $1,320 |
| Otsuka America Pharmaceutical, Inc. | 47 | $905 |
| Takeda Pharmaceuticals U.S.A., Inc. | 38 | $698 |
| Teva Pharmaceuticals USA, Inc. | 29 | $695 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $640 |
| Alkermes, Inc. | 24 | $500 |
| Corium, LLC | 24 | $434 |
| Lundbeck LLC | 11 | $249 |
| E.r. Squibb & Sons, L.L.C. | 8 | $219 |
| Eisai Inc. | 12 | $202 |
| Ironshore Pharmaceuticals Inc. | 11 | $192 |
| Neos Therapeutics, LP | 9 | $139 |
| Vanda Pharmaceuticals Inc. | 7 | $133 |
| Silk Road Medical, Inc. | 1 | $97 |
| Bausch Health US, LLC | 5 | $96 |
| Indivior Inc. | 4 | $88 |
| Janssen Scientific Affairs, LLC | 3 | $79 |
| Almatica Pharma LLC | 3 | $56 |
| Acadia Pharmaceuticals Inc | 2 | $42 |
| Supernus Pharmaceuticals, Inc. | 2 | $39 |
| Noven Therapeutics, LLC | 2 | $35 |
| Shire North American Group Inc | 2 | $30 |
| Brainsway USA Inc | 1 | $28 |
| Sage Therapeutics, LLC | 1 | $24 |
| Tris Pharma Inc | 1 | $19 |
| Adlon Therapeutics L.p. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$190,122
- Auvelity$121,284
- LATUDA$18,774
- BELSOMRA$2,903
- VNS Therapy$1,148
- INGREZZA$247
- VNS - Symmetry$150
- VRAYLAR$125
How this compares
$355,028 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 28 | $50,438 |
| TrintellixVortioxetine Hydrobromide | 14 | $11,768 |
| DayvigoLemborexant | 13 | $4,106 |
| Quetiapine Fumarate | 81 | $1,293 |
| Duloxetine Hcl | 46 | $1,251 |
| Bupropion XlBupropion Hcl | 56 | $1,225 |
| Aripiprazole | 51 | $1,214 |
| Mirtazapine | 69 | $1,054 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 14 | $743 |
| Oxcarbazepine | 17 | $596 |
| Clonazepam | 105 | $503 |
| Buspirone Hcl | 75 | $459 |
| Escitalopram Oxalate | 49 | $430 |
| Lamotrigine | 26 | $408 |
| Trazodone Hcl | 64 | $393 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $194,702 | $50,43828 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $698 | $11,76814 claims |
| Eisai Inc.Dayvigo | $202 | $4,10613 claims |
| Almatica Pharma LLCSertraline Hcl | $56 | $32749 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Houston
- Matthew BramsHouston$1.5M
- Frank ChenHouston$941K
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
- Barry GritzHouston$792K
- Aaron PetersonHouston$700K
- Ayesha RashidHouston$641K
- Lawrence GinsbergHouston$502K
- Kathy FlanaganHouston$443K
- Rayan Al JurdiHouston$359K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.